Rational Therapeutics Based on Matched Tumor and Normal Tissue

Completed

Conditions studied: Advanced Cancers

In brief

The goal of this laboratory research study is to learn if using molecular information (matched therapy) or not using molecular information and having the study doctor choose the therapy based on your past experience are more effective ways to choose the best cancer treatment for you. This is an investigational study. Up to 200 participants will take part in this study. Up to 50 will be enrolled at MD Anderson.

Key facts

Study ID

NCT02272595

Run by

M.D. Anderson Cancer Center

People needed

3

Starts

2014-11-04

Expected to finish

2022-01-11

Last updated by the study team

2022-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent
• Any histologic type of metastatic cancer, (except for lung and brain at US sites), in which histologic normal counterpart can be obtained. See list of cancer types included in the trial in Appendix 1.
• Progression by RECIST (Response Evaluation Criteria In Solid Tumors) or other criteria on at least one prior regimen for advanced disease
• Ability to undergo a biopsy or surgical procedure to obtain fresh tumor biopsy paired with its normal counterpart
• Age from 18 years
• Life expectancy of at least 3 months
• ECOG Performance status of 0 to 1
• Measurable or evaluable disease according to RECIST 1.1 criteria
• For US sites only: advanced cancer patients that have exhausted all effective therapy for their disease and have progressed after previous line of therapy (documented disease progression under last treatment received) and conventional methods of assigning new therapy would not be expected to increase survival by more than 3 months.

You may not qualify if…

• For US sites only: Any patient that might require a lung or brain biopsy are excluded
• Alteration of organ function or hematopoietic function as defined by the following criteria:
• Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) >2.5 x upper limit of normal (ULN), except for patients with liver metastases, for which AST and ALT > 5.0 ULN is the exclusion criteria.
• Bilirubin > 2.0 ULN to allow for Gilberts
• Polynuclear neutrophil < 1.5 x 109/L
• Platelets < 100 x 10 9/L
• Hemoglobin < 90 g/L
• Creatinine > 1.5 ULN
• i. Calcemia > 1.5 ULN g. Phosphatemia > 1.5 ULN
• Coagulation abnormality prohibiting a biopsy
• Symptomatic or progressive brain metastases detected by radio imaging, or meningeal
• Patient who received a personalized therapeutic treatment based on molecular anomaly during the treatment period immediately prior to the WINTHER directed treatment (defining the PFS1). Hormonal therapy may be continued during WINTHER suggested therapy. The exclusion of prior matched targeted therapy includes but is not limited to all targeted therapeutics that are EMA approved and genomically matched to patients. If there are questions about whether or not a prior therapy is a matched targeted treatment it will be agreed on by discussion between PIs who are also Clinical Management Committee members; the resolution should take place prior to starting Winther directed treatment.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Cancer Institute Gustave Roussy — Villejuif, France
• Chaim Sheba Medical Center at Tel Hasomer — Ramat Gan, Israel
• Vall D'Hebron University Hospital — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.